Skip to main content
Erschienen in: The International Journal of Cardiovascular Imaging 7/2020

08.05.2020 | Original Paper

Characterization of Fabry Disease cardiac involvement according to longitudinal strain, cardiometabolic exercise test, and T1 mapping

verfasst von: Patricia Réant, Emilie Testet, Amélie Reynaud, Catherine Bourque, Matthieu Michaud, Caroline Rooryck, Cyril Goizet, Didier Lacombe, Valérie de-Précigout, Jérôme Peyrou, Hubert Cochet, Stéphane Lafitte

Erschienen in: The International Journal of Cardiovascular Imaging | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

In Anderson-Fabry disease (FD), we sought to evaluate relation between left ventricular (LV) hypertrophy, longitudinal strain (LS), myocardial T1 mapping and cardiopulmonary exercise parameters, and their prognostic value in term of cardiovascular outcomes. In this prospective, observational, monocentric study called “FABRY-Image”, we evaluated consecutive adult FD patients by echocardiography, cardiac magnetic resonance, and cardiopulmonary exercise testing. We investigated regional LS, the relations between LV hypertrophy, LS, T1 mapping, and VO2 peak and VE/VCO2, and the prediction of cardiovascular events during follow-up. From 2016 to 2019, we included 35 FD patients (44 ± 17 years, 40% male), that were compared with 20 controls. In FD patients, global, basal and mid-LV LS, as well as mean T1 were significantly altered compared to controls (p < 0.05) with relative apical LS sparing. LV wall thickness was particularly related to mean of basal LS (r =  − 0.73), to T1 (r =  − 0.48), and to VE/VCO2 (r = 0.45). Mean of basal LS was well related to myocardial T1 (r = 0.59). A good relation was observed between VO2 peak and global LS (r = 0.39) while VE/VCO2 slope was more related to maximal LV wall thickness (r = 0.45), and T1 (r =  − 0.61). During a median follow-up of 2.4 years, 6/31 patients presented de novo atrial fibrillation or stroke. In Cox univariate analyses, LV wall thickness, basal LS, T1 value, and VE/VCO2 were significantly predictive of occurrence of de novo atrial fibrillation or stroke (p < 0.05). Our study shows an apical LS sparing in FD patients as observed in amyloidosis, and a close relation between LV hypertrophy, LS, T1 mapping, and VE/VCO2 which are all associated to the occurrence of de novo atrial fibrillation or TIA/stroke during follow-up. These results need to be confirmed by future multicentric studies.
Literatur
1.
Zurück zum Zitat Brady RO, Gal AE, Bradley RM et al (1967) Enzymatic defect in Fabry’s disease Ceramidetrihexosidase deficiency. N Engl J Med 276:1163–1167CrossRef Brady RO, Gal AE, Bradley RM et al (1967) Enzymatic defect in Fabry’s disease Ceramidetrihexosidase deficiency. N Engl J Med 276:1163–1167CrossRef
2.
Zurück zum Zitat Zarate YA, Hopkin RJ (2008) Fabry’s disease. Lancet 372:1427–1435CrossRef Zarate YA, Hopkin RJ (2008) Fabry’s disease. Lancet 372:1427–1435CrossRef
3.
Zurück zum Zitat Houge G, Skarbovik AJ (2005) Fabry disease: a diagnostic and therapeutic challenge. Tidsskr Nor Laegeforen 125:1004–1006PubMed Houge G, Skarbovik AJ (2005) Fabry disease: a diagnostic and therapeutic challenge. Tidsskr Nor Laegeforen 125:1004–1006PubMed
5.
Zurück zum Zitat Patel MR, Cecchi F, Cizmarik M et al (2011) Cardiovascular events in patients with Fabry disease natural history data from the fabry registry. J Am Coll Cardiol 57:1093–1099CrossRef Patel MR, Cecchi F, Cizmarik M et al (2011) Cardiovascular events in patients with Fabry disease natural history data from the fabry registry. J Am Coll Cardiol 57:1093–1099CrossRef
6.
Zurück zum Zitat Waldek S, Patel MR, Banikazemi M et al (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11:790–796CrossRef Waldek S, Patel MR, Banikazemi M et al (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11:790–796CrossRef
7.
Zurück zum Zitat Thurberg BL, Fallon JT, Mitchell R et al (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119:2561–2567CrossRef Thurberg BL, Fallon JT, Mitchell R et al (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119:2561–2567CrossRef
8.
Zurück zum Zitat Hughes DA, Elliott PM, Shah J (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo controlled clinical trial of agalsidase alfa. Heart 94:153–158CrossRef Hughes DA, Elliott PM, Shah J (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo controlled clinical trial of agalsidase alfa. Heart 94:153–158CrossRef
9.
Zurück zum Zitat Yeung DF, Sirrs S, Tsang MYC et al (2018) Echocardiographic assessment of patients with Fabry disease. J Am Soc Echocardiogr 31:639–649CrossRef Yeung DF, Sirrs S, Tsang MYC et al (2018) Echocardiographic assessment of patients with Fabry disease. J Am Soc Echocardiogr 31:639–649CrossRef
10.
Zurück zum Zitat Shanks M, Thompson RB, Paterson ID et al (2013) Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Am Soc Echocardiogr 26:1407–1414CrossRef Shanks M, Thompson RB, Paterson ID et al (2013) Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Am Soc Echocardiogr 26:1407–1414CrossRef
11.
Zurück zum Zitat Saccheri MC, Cianciulli TF, Lax JA et al (2013) Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease. Echocardiography 30:1069–1077PubMed Saccheri MC, Cianciulli TF, Lax JA et al (2013) Two-dimensional speckle tracking echocardiography for early detection of myocardial damage in young patients with Fabry disease. Echocardiography 30:1069–1077PubMed
12.
Zurück zum Zitat Kozor R, Grieve SM, Tchan MC et al (2016) Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR. Heart 102:298–302CrossRef Kozor R, Grieve SM, Tchan MC et al (2016) Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR. Heart 102:298–302CrossRef
13.
Zurück zum Zitat Moon JC, Sheppard M, Reed E et al (2006) The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 8:479CrossRef Moon JC, Sheppard M, Reed E et al (2006) The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 8:479CrossRef
14.
Zurück zum Zitat Deva DP, Hanneman K, Li Q et al (2016) Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson 18:14CrossRef Deva DP, Hanneman K, Li Q et al (2016) Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. J Cardiovasc Magn Reson 18:14CrossRef
15.
Zurück zum Zitat Kramer J, Niemann M, Stork S et al (2014) Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol 114:895–900CrossRef Kramer J, Niemann M, Stork S et al (2014) Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol 114:895–900CrossRef
16.
Zurück zum Zitat Pica S, Sado DM, Maestrini V et al (2014) Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 16:99CrossRef Pica S, Sado DM, Maestrini V et al (2014) Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 16:99CrossRef
17.
Zurück zum Zitat Whybra C, Kampmann C, Krummenauer F et al (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307CrossRef Whybra C, Kampmann C, Krummenauer F et al (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307CrossRef
18.
Zurück zum Zitat Nishimura R, Miller FJ, Callahan M et al (1985) Doppler echocardiography: theory, instrumentation technique and application. Mayo Clin Proc 60:321–343CrossRef Nishimura R, Miller FJ, Callahan M et al (1985) Doppler echocardiography: theory, instrumentation technique and application. Mayo Clin Proc 60:321–343CrossRef
19.
Zurück zum Zitat Tajik A, Seward J, Hagler D et al (1978) Two dimensional real-time ultrasonic imaging of the heart and great vessels: technique, image orientation, structure identification and validation. Mayo Clin Proc 53:271–303PubMed Tajik A, Seward J, Hagler D et al (1978) Two dimensional real-time ultrasonic imaging of the heart and great vessels: technique, image orientation, structure identification and validation. Mayo Clin Proc 53:271–303PubMed
20.
Zurück zum Zitat Lang RM, Bierig M, Devereux RB et al (2015) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRef Lang RM, Bierig M, Devereux RB et al (2015) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRef
21.
Zurück zum Zitat Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107–133CrossRef Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107–133CrossRef
22.
Zurück zum Zitat Rudski LG, Lai WW, Afilalo J et al (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23:685–713CrossRef Rudski LG, Lai WW, Afilalo J et al (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23:685–713CrossRef
23.
Zurück zum Zitat Kozor R, Callaghan F, Tchan M et al (2015) A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease. J Cardiovasc Magn Reson 17:22CrossRef Kozor R, Callaghan F, Tchan M et al (2015) A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease. J Cardiovasc Magn Reson 17:22CrossRef
24.
Zurück zum Zitat Wasserman K, Hansen JE, Sue D et al (2004) Principles of exercise testing and interpretation, 4th edn. Lippincott Williams and Wilkins, Philadelphia Wasserman K, Hansen JE, Sue D et al (2004) Principles of exercise testing and interpretation, 4th edn. Lippincott Williams and Wilkins, Philadelphia
25.
Zurück zum Zitat De Cobelli F, Esposito A, Belloni E et al (2009) Delayed-enhanced cardiac MRI for differentiation of Fabry’s disease from symmetric hypertrophic cardiomyopathy. Am J Roentgenol 192:W97–102CrossRef De Cobelli F, Esposito A, Belloni E et al (2009) Delayed-enhanced cardiac MRI for differentiation of Fabry’s disease from symmetric hypertrophic cardiomyopathy. Am J Roentgenol 192:W97–102CrossRef
26.
Zurück zum Zitat Phelan D, Collier P, Thavendiranathan P et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98:1442–1448CrossRef Phelan D, Collier P, Thavendiranathan P et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98:1442–1448CrossRef
27.
Zurück zum Zitat Krämer J, Niemann M, Liu D et al (2013) Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J 34:1587–1596CrossRef Krämer J, Niemann M, Liu D et al (2013) Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J 34:1587–1596CrossRef
28.
Zurück zum Zitat Cohn JN, Johnson GR, Shabetai R et al (1993) Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 87(6):I15–16 Cohn JN, Johnson GR, Shabetai R et al (1993) Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 87(6):I15–16
29.
Zurück zum Zitat Arena R, Myers J, Aslam SS et al (2004) Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J 147:354–360CrossRef Arena R, Myers J, Aslam SS et al (2004) Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J 147:354–360CrossRef
30.
Zurück zum Zitat Lobo T, Morgan J, Bjorksten A et al (2008) Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement. Intern Med J 38:407–414CrossRef Lobo T, Morgan J, Bjorksten A et al (2008) Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement. Intern Med J 38:407–414CrossRef
31.
Zurück zum Zitat Myers J, Kaminsky L, Lima R et al (2017) A reference equation for normal standards for VO2 max: analysis from the fitness registry and the importance of exercise national database (FRIEND Registry). Prog Cardiovasc Dis 60:21–29CrossRef Myers J, Kaminsky L, Lima R et al (2017) A reference equation for normal standards for VO2 max: analysis from the fitness registry and the importance of exercise national database (FRIEND Registry). Prog Cardiovasc Dis 60:21–29CrossRef
32.
Zurück zum Zitat Koch B, Schaper C, Ittermann T et al (2008) Reference values for cardiopulmonary exercise testing in healthy volunteers: the SHIP study. Eur Respir J 33:389–397CrossRef Koch B, Schaper C, Ittermann T et al (2008) Reference values for cardiopulmonary exercise testing in healthy volunteers: the SHIP study. Eur Respir J 33:389–397CrossRef
33.
Zurück zum Zitat Vijapurapu R, Geberhiwot T, Jovanovic A et al (2019) Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart 105:1825–1831CrossRef Vijapurapu R, Geberhiwot T, Jovanovic A et al (2019) Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart 105:1825–1831CrossRef
Metadaten
Titel
Characterization of Fabry Disease cardiac involvement according to longitudinal strain, cardiometabolic exercise test, and T1 mapping
verfasst von
Patricia Réant
Emilie Testet
Amélie Reynaud
Catherine Bourque
Matthieu Michaud
Caroline Rooryck
Cyril Goizet
Didier Lacombe
Valérie de-Précigout
Jérôme Peyrou
Hubert Cochet
Stéphane Lafitte
Publikationsdatum
08.05.2020
Verlag
Springer Netherlands
Erschienen in
The International Journal of Cardiovascular Imaging / Ausgabe 7/2020
Print ISSN: 1569-5794
Elektronische ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-020-01823-7

Weitere Artikel der Ausgabe 7/2020

The International Journal of Cardiovascular Imaging 7/2020 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.